Mike Romanos wins promotion

Becomes chief executive of Crescendo Biologics

Crescendo Biologics has appointed Mike Romanos as chief executive.

Romanos has been chief scientific officer of the Cambridge, UK-based company since May 2009 and has led its formation and the development of its proprietary antibody fragment technologies.

Since 2009 Crescendo has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. These ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

Romanos has more than 23 years’ biotech and pharma industry experience and within the last 10 years has held senior global positions leading major parts of GlaxoSmithKline Discovery.

You may also like

Research & Development

Crescendo Biologics announces cancer research collaboration

Dr Andrew Pierce, VP Translational Biology at Crescendo, said: “The ICR is a world-renowned research institution, and we are very excited to have the opportunity to collaborate with Professor de Bono and his team"
Research & Development

Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda

Crescendo, the developer of multifunctional biologics, including targeted T-cell engagers, has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company
Research & Development

Crescendo Biologics expands ADC programmes with Innovate UK grant

Award will support development of new therapies to target prostate cancer
Research & Development

Multi million pound seed funding enables Crescendo Biologics to advance fragment antibody technology

<p>Crescendo Biologics has raised £4.5m in a seed funding round
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Subscribe now